论文部分内容阅读
目的观察以氟达拉宾为主的联合化疗方案对惰性淋巴瘤的疗效及临床耐受性。方法予133例惰性淋巴瘤患者氟达拉宾联合环磷酰胺(FC方案)或氟达拉宾联合米托蒽醌及地塞米松(FMD方案)治疗2～6个疗程,观察其疗效及不良反应。结果初治患者完全缓解(CR)率为55．6%(25例),部分缓解(PR)率为42．2% (19例),总体有效(OR)率为97．8%(44例)。复发难治患者的CR、PR和OR率分别为48．9%(43例)、40．9% (36例)和89．8%(79例)。完成2～4个疗程者的CR率为24%～47%,完成5～7个疗程者的CR率达59%～100%。不良反应主要为中性粒细胞减少、贫血和血小板减少。结论以氟达拉宾为主的联合化疗治疗初治及复发难治惰性淋巴瘤患者的缓解率高,且具有良好的安全性。
Objective To observe the efficacy and clinical tolerance of fludarabine-based combination chemotherapy in patients with indolent lymphoma. Methods 133 cases of indolent lymphoma patients treated with fludarabine combined with cyclophosphamide (FC regimen) or fludarabine combined mitoxantrone and dexamethasone (FMD regimen) for 2 to 6 courses of treatment to observe its efficacy and poor reaction. Results The rate of complete remission (CR) in initial treatment was 55.6% (25 cases), partial remission (PR) was 42.2% (19 cases) and the overall effective rate was 97.8% (44 cases ). The CR, PR and OR rates of refractory and relapsed patients were 48.9% (43 cases), 40.9% (36 cases) and 89.8% (79 cases), respectively. Completion of 2 to 4 courses of CR rate was 24% to 47%, completed 5 to 7 courses CR rate of 59% to 100%. Adverse reactions are mainly neutropenia, anemia and thrombocytopenia. Conclusion Fludarabine-based combination chemotherapy in patients with newly diagnosed and refractory refractory indolent lymphoma has a high remission rate and good safety.